Knockdown of Pyruvate Kinase M Inhibits Cell Growth and Migration by Reducing NF-kB Activity in Triple-Negative Breast Cancer Cells

다국어 초록 (Multilingual Abstract)

Altered genetic features in cancer cells lead to a high rate of aerobic glycolysis and metabolic reprogramming that is essential for increased cancer cell viability and rapid proliferation. Pyruvate kinase muscle (PKM) is a rate-limiting enzyme in the final step of glycolysis. Herein, we report that PKM is a potential therapeutic target in triple-negative breast cancer (TNBC) cells. We found that PKM1 or PKM2 is highly expressed in TNBC tissues or cells. Knockdown of PKM significantly suppressed cell proliferation and migration, and strongly reduced S phase and induced G2 phase cell cycle arrest by reducing phosphorylation of the CDC2 protein in TNBC cells. Additionally, knockdown of PKM significantly suppressed NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) activity by reducing the phosphorylation of p65 at serine 536, and also decreased the expression of NF-kB target genes. Taken together, PKM is a potential target that may have therapeutic implications for TNBC cells.

참고문헌 (Reference)

1 Vander Heiden, M. G., "Understanding the Warburg effect : the metabolic requirements of cell proliferation" 324 : 1029-1033, 2009

2 Kroemer, G., "Tumor cell metabolism : cancer's Achilles' heel" 13 : 472-482, 2008

3 Ito-Kureha, T., "Tropomodulin 1 expression driven by NF-kappaB enhances breast cancer growth" 75 : 62-72, 2015

4 Bianchini, G., "Triple-negative breast cancer : challenges and opportunities of a heterogeneous disease" 13 : 674-690, 2016

5 Okazaki, M., "The effect of HIF-1alpha and PKM1 expression on acquisition of chemoresistance" 10 : 1865-1874, 2018

6 DeBerardinis, R. J., "The biology of cancer : metabolic reprogramming fuels cell growth and proliferation" 7 : 11-20, 2008

7 Christofk, H. R., "The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth" 452 : 230-233, 2008

8 Israel, A., "The IKK complex, a central regulator of NF-kappaB activation" 2 : a000158-, 2010

9 Tennant, D. A., "Targeting metabolic transformation for cancer therapy" 10 : 267-277, 2010

10 Barbie, T. U., "Targeting an IKBKE cytokine network impairs triple-negative breast cancer growth" 124 : 5411-5423, 2014

11 Hayden, M. S., "Shared principles in NF-kappaB signaling" 132 : 344-362, 2008

12 Kuo, W. Y., "STAT3/NF-kappaB-regulated lentiviral TK/GCV suicide gene therapy for Cisplatin-resistant triple-negative breast cancer" 7 : 647-663, 2017

13 Chaneton, B., "Rocking cell metabolism : revised functions of the key glycolytic regulator PKM2 in cancer" 37 : 309-316, 2012

14 Mazurek, S., "Pyruvate kinase type M2: a key regulator within the tumour metabolome and a tool for metabolic profiling of tumours" (4) : 99-124, 2007

15 Mazurek, S., "Pyruvate kinase type M2 : a key regulator of the metabolic budget system in tumor cells" 43 : 969-980, 2011

16 Kim, D. J., "Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells" 336 : 119-129, 2015

17 Chiavarina, B., "Pyruvate kinase expression(PKM1 and PKM2)in cancer-associated fibroblasts drives stromal nutrient production and tumor growth" 12 : 1101-1113, 2011

18 Gao, X., "Pyruvate kinase M2regulates gene transcription by acting as a protein kinase" 45 : 598-609, 2012

19 Luo, W., "Pyruvate kinase M2 regulates glucose metabolism by functioning as a coactivator for hypoxia-inducible factor 1in cancer cells" 2 : 551-556, 2011

20 Luo, W., "Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1" 145 : 732-744, 2011

21 Nabel, G. J., "Proposed NF-kappa B/I kappa B family nomenclature" 7 : 2063-, 1993

22 Chang, B., "Prolonged progression-free survival in a patient with triple-negative breast cancer metastatic to the liver after chemotherapy and local radiation therapy" 14 : e61-e64, 2014

23 Azoitei, N., "PKM2 promotes tumor angiogenesis by regulating HIF-1alpha through NF-kappaB activation" 15 : 3-, 2016

24 Yang, W., "PKM2 phosphorylates histone H3and promotes gene transcription and tumorigenesis" 150 : 685-696, 2012

25 Harris, I., "PKM2 : a gatekeeper between growth and survival" 22 : 447-449, 2012

26 Morita, M., "PKM1 confers metabolic advantages and promotes cell-autonomous tumor cell growth" 33 : 355.e7-367.e7, 2018

27 Zhou, Z., "Oncogenic kinase-induced PKM2 tyrosine 105phosphorylation converts nononcogenic PKM2 to a tumor promoter and induces cancer stem-like cells" 78 : 2248-2261, 2018

28 Han, D., "NF-kappaB/RelA-PKM2 mediates inhibition of glycolysis by fenofibrate in glioblastoma cells" 6 : 26119-26128, 2015

29 Tennant, D. A., "Metabolic transformation in cancer" 30 : 1269-1280, 2009

30 Bonotto, M., "Measures of outcome in metastatic breast cancer : insights from a real-world scenario" 19 : 608-615, 2014

31 Dang, C. V., "Links between metabolism and cancer" 26 : 877-890, 2012

32 Wang, H. J., "JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1alpha-mediated glucose metabolism" 111 : 279-284, 2014

33 House, C. D., "IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts" 18 : 595-, 2018

34 Anastasiou, D., "Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses" 334 : 1278-1283, 2011

35 King, A., "Glucose metabolism and programmed cell death : an evolutionary and mechanistic perspective" 21 : 885-893, 2009

36 Wu, X., "Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways" 6 : 29143-29160, 2015

37 Yang, W., "ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect" 14 : 1295-1304, 2012

38 Yamaguchi, N., "Constitutive activation of nuclear factor-kappaB is preferentially involved in the proliferation of basal-like subtype breast cancer cell lines" 100 : 1668-1674, 2009

39 Tutt, A., "Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups : the TNT Trial" 24 : 628-637, 2018

40 Fantin, V. R., "Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance" 9 : 425-434, 2006

41 Lebert, J. M., "Advances in the systemic treatment of triple-negative breast cancer" 25 (25): S142-S150, 2018

42 Lv, L., "Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth" 42 : 719-730, 2011

43 Qiao, Y., "AP-1 is a key regulator of Proinflammatory cytokine TNFalphamediated triple-negative breast cancer progression" 291 : 5068-5079, 2016